Back to Search Start Over

AQP3 and AQP9-Contrary Players in Sepsis?

Authors :
Thon P
Rahmel T
Ziehe D
Palmowski L
Marko B
Nowak H
Wolf A
Witowski A
Orlowski J
Ellger B
Wappler F
Schwier E
Henzler D
Köhler T
Zarbock A
Ehrentraut SF
Putensen C
Frey UH
Anft M
Babel N
Sitek B
Adamzik M
Bergmann L
Unterberg M
Koos B
Rump K
Source :
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 19; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 19.
Publication Year :
2024

Abstract

Sepsis involves an immunological systemic response to a microbial pathogenic insult, leading to a cascade of interconnected biochemical, cellular, and organ-organ interaction networks. Potential drug targets can depict aquaporins, as they are involved in immunological processes. In immune cells, AQP3 and AQP9 are of special interest. In this study, we tested the hypothesis that these aquaporins are expressed in the blood cells of septic patients and impact sepsis survival. Clinical data, routine laboratory parameters, and blood samples from septic patients were analyzed on day 1 and day 8 after sepsis diagnosis. AQP expression and cytokine serum concentrations were measured. AQP3 mRNA expression increased over the duration of sepsis and was correlated with lymphocyte count. High AQP3 expression was associated with increased survival. In contrast, AQP9 expression was not altered during sepsis and was correlated with neutrophil count, and low levels of AQP9 were associated with increased survival. Furthermore, AQP9 expression was an independent risk factor for sepsis lethality. In conclusion, AQP3 and AQP9 may play contrary roles in the pathophysiology of sepsis, and these results suggest that AQP9 may be a novel drug target in sepsis and, concurrently, a valuable biomarker of the disease.

Details

Language :
English
ISSN :
1422-0067
Volume :
25
Issue :
2
Database :
MEDLINE
Journal :
International journal of molecular sciences
Publication Type :
Academic Journal
Accession number :
38279209
Full Text :
https://doi.org/10.3390/ijms25021209